Skip to main content

Table 3 Comparison of NSE levels to predict poor outcome after cardiac arrest and referenced study profiles

From: Serum neuron-specific enolase as predictor of outcome in comatose cardiac-arrest survivors: a prospective cohort study

Référence In-hospital CPR (%) Time of inclusion after CPR,
n
Hypothermic therapy,
n
Follow-up Poor outcome definition, and number
n
Method used for NSE measurement NSE sampling time Cut-off value (ng/mL) Se Sp
Fogel et al.
[10] 1997
Not specified ICU admission
n = 43
No 3 months Remained comatose
n = 25
Radioimmunoassay, Pharmacia LKB Day 0
Day 1
Day 2
Day 3
33
33
33
33
25
60
63
65
100
100
100
100
Martens et al.
[21] 1998
Not specified > 24 h
n = 64
No 6 months Remained comatose
n = 35
Radioimmunoassay, Profilogen 24 h 20 51 89
Schoerkhber et al. [11] 1999 Yes (not specified) > 6 h
n = 56
No 6 months CPC 3-5
n = 28
Radioimmunoassay, Profilogen 12 h
24 h
48 h
72 h
Peak NSE level 12-72 h
38
40
25
17
27
18
8
48
70
29
100
100
100
100
100
Rosen et al.
[12] 2001
No > 24 h
n = 66
No 1 year CPC 3-5
n = 42
Imunoluminometric assay, Byk Sangtec Diagnostica Day1
Day2
Day3
25
25
25
NM
NM
NM
100
100
100
Zingler et al.
[15]2003
Yes (not specified) ICU admission
n = 27
No 3 months CPC 4-5
n = 17
Immunoluminometric assay, Byk Sangtec Diagnostica Day1
Day2
Day3
Day7
48
43
91
39
53
91
75
57
100
100
100
100
Tiainem et al.
[14] 2003
No* ICU admission
n = 70
Yes
n = 36
6 months CPC 3-5
n = 29
time-resolved immunofluorometric assay (DELFIA, Wallac) 24 h HT/no HT
36 h HT/no HT
48 h HT/no HT
31/13
26/13
25/9
22/59
30/63
25/76
96/100
96/100
96/100
Meynaar et al.
[13] 2003
Yes (23%) ICU admission
n = 110
No Hospital
discharge
Remained comatose
n = 81
time-resolved immunofluorometric assay (DELFIA, Wallac) Peak NSE level 24-48 h¶ 25 59 100
Pfeifer et al.
[16]2005
Yes (44%) > 48 h
n = 97
Not specified Day 28 CPC 4-5
n = 70
Imunoluminometric assays, Byk Sangtec Diagnostica Day 3 65 50 96
Rech at al.
[17]2006
Yes (100%) >12 h
n = 45
No 6 months CPC 4-5
n = 34
Electrochemiluminescence immunoassay, Roche Mannheim Between 12-36 h 60 35 100
Zandbergen et al
[2]2006
Not specified > 24 h
n = 407
Yes (not specified) 1 months CPC 4-5
n = 356
Immunoluminometric assay, Byk Sangtec Diagnostica 24 h
48 h
72 h
>33
>33
>33
42
52
46
100
100
100
Auer et al.
[18] 2006
Yes (not specified) n = 17 Not specified Hospital
discharge
Death
n = 9
Electrochemiluminescence immunoassay, Roche Mannheim 48 h 30 79 100
Grubb et al.
[23] 2007
No ICU admission
n = 143
Not specified Hospital
discharge
Death Enzyme immunoassay, Roche Diagnostics 12 h
24-48 h
72-96 h
NM
71
NM
14 100
Reisinger et al.
[19]2007
Yes (44%) ICU admission
n = 177
Yes
n = 20
6 months CPC 4-5
n = 59
Electrochemiluminescence immunoassay, Roche Mannheim Peak NSE level
Day 0-4
80 63 100
Oksanen et al.
[20] 2009
No* ICU admission
n = 90
Yes
n = 90
6 months CPC 3-5
n = 40
Electrochemiluminescence immunoassay, Roche Mannheim 24 h
48 h
41
33
20
43
100
100
Rundgren et al.
[9] 2009
Yes (17%) ICU admission
n = 102
(for NSE cohort)
Yes
n = 102
6 months CPC 3-5
n = 46
Imunoluminometric assay, DiaSorin 2 h
24 h
48 h
72 h
31
38
28
27
6
11
67
50
100
100
100
100
Shinozaki et al.
[22] 2009
Yes (27%) ICU admission
n = 80
Yes
n = 45
6 months CPC 3-5
n = 67
Immunoradiometric assay, Profilogen, DiaSorin Admission
6 h
24 h
46
66
40
14
19
72
100
100
100
Steffen et al
[42] 2010
Yes (21%) ICU admission
n = 240
Yes
n = 133
ICU discharge CPC 3-5
n = 147
Electrochemiluminescence immunoassay, Roche Mannheim 72 h HT/no HT 79/27 50
80
100
100
Present study Yes (31%) > 48 h
n = 97
Yes
n = 65
3 months CPC 4-5
n = 72
Electrochemiluminescence immunoassay, Roche Mannheim Peak NSE level 24-72 h 97 49 100
  1. HT; hypothermic therapy, NM; not mentioned
  2. * Only ventricular fibrillation as initial rhythm was eligible for the study
  3. Results mentioned only for patients who remained comatose 48 hours after CPR (n = 67)